Health Trials

Predictive Factors for Treatment Response in Patients With Newly-diagnosed Polymyalgia Rheumatica and Giant Cell Arteritis

ConditionsPolymyalgia Rheumatica (PMR)Giant Cell Arteritis (GCA)
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity Hospital, Basel, Switzerland

About this trial

This prospective study is to explore different predictive factors for response to steroid treatment in patients with PMR and/or GCA. It evaluates the association of endogenous GC suppression (plasma and urinary cortisol and cortisone) to the responsiveness of PMR/GCA to GCs.

Eligibility criteria

Qualifiers

Patients with diagnosis of PMR according to the 2012 provisional classification criteria and GCA according to published criteria

Consent to participate in the SCQM database

Treatment according to our standardized regimes

Disqualifiers

Treatment with Tocilizumab, MTX or other disease modifying medications at inclusion

History of GCA and PMR in the past

Inability to give informed consent

Trial design

Treatments tested in this trial

  • Data collection for cellular analyses (Immune subset composition, GCR expression, in vitro steroid responsiveness)
  • Data collection for exploratory analyses of endogenous steroid hormones
  • Data collection for correlation between clinical defined and lab defined GC responsivness
  • Data collection for Prednisone metabolism

Treatment groups

No treatment groups listed

Sponsors and collaborators

University Hospital, Basel, Switzerland

Lead sponsor

Schweizerische Stiftung für die Erforschung der Muskelkrankheiten

Collaborator

Novartis

Collaborator

Source ClinicalTrials.gov